Among 67 children treated with Bluebird Bio's gene therapy for a rare neurological disease, seven have developed blood cancer so far, with one child unfortunately passing away.

The TnpB system is not only small in size but also possesses powerful gene-editing capabilities, bringing a new breakthrough to gene-editing technology.

Recently, David Liu's team has made another breakthrough in gene editing technology. The new system, eePASSIGE, can insert exogenous fragments up to 10kb in length, with an integration efficiency 16 times higher than previous systems.